Quantcast

US Oncology Research Affiliated Physician to Present Innovative Oral Clinical Study at 2010 San Antonio Breast Cancer Symposium

December 8, 2010

THE WOODLANDS, Texas, Dec. 8, 2010 /PRNewswire/ — World-class investigators affiliated with US Oncology Research participated in studies that will be presented, discussed and displayed Dec. 8-12 at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), an international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.

(Logo: http://photos.prnewswire.com/prnh/20100517/DA06089LOGO)

Joyce O’Shaughnessy, M.D., medical director and co-chair of the Breast Cancer Research Committee, US Oncology Research, and medical oncologist with Texas Oncology-Baylor Sammons Cancer Center, will present her study findings regarding an innovative ten-year analysis focusing on high-risk early breast cancer in an oral presentation at 3:30 pm CST, Friday, Dec. 10. The study titled “First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide Followed by Docetaxel with or without Capecitabine in High-Risk Early Breast Cancer” provides an in-depth look at how faster growing breast cancers react to Xeloda® (capecitabine).

In addition to the above oral presentation, Dr. O’Shaughnessy and many other US Oncology Research affiliated investigators participated in the following studies that will be displayed as posters and poster discussions at the conference:


    -- Poster Discussions:
                   7:00 am CST, Saturday, Dec. 11: A Genomic Predictor of
                   Survival Following Taxane-Anthracycline Chemotherapy for
                   Breast Cancer
                   -- Symmans WF, Hatzis C, Valero V, Booser DJ, Esserman L,
                   Martin M, Vidaurre T, Holmes F, Souchon EA, Lluch A,
                   Cotrina J, Gomez H, Hubbard R, Ferrer-Lozano J, Dyer R,
                   Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT,
                   Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J,
                   Hortobagyi GN, Pusztai L.(1)
                   5:30 pm CST, Thursday, Dec. 9: Review of Capecitabine for
                   the Treatment of Triple-Negative Early Breast Cancer
                  -- Steger GG, Barrios C, O'Shaughnessy J, Martin M, Gnant M.
    -- Posters:
                   7:00 am CST, Saturday, Dec. 11: A Pilot Safety and
                   Feasibility Study of Concurrent Capecitabine and External
                   Beam Irradiation in the Adjuvant Treatment of High Risk
                   Early Stage Breast Cancer
                   --Garwood DP, Spangler A, DeRose PM, Li HC, Osborne C,
                   O'Shaughnessy J, Tripathy D.
                   7:00 am CST, Sunday, Dec. 12: Impact of the Number of Prior
                   Chemotherapy Regimens on Overall Survival (OS) among
                   Subjects with Locally Recurrent or Metastatic Breast Cancer
                   Treated with Eribulin Mesylate: Results from the Phase III
                   EMBRACE Study
                   --Blum JL, Twelves CJ, Akerele C, Seegobin S, Wanders J,
                   Cortes J.
                   7:00 am CST, Sunday, Dec. 12: Meta-analysis of patients
                   with triple-negative disease from three randomized trials
                   of bevacizumab (BV) and first-line chemotherapy as
                   treatment for metastatic breast cancer (MBC)
                   -- J O'Shaughnessy, G Romieu, V Dieras, M Byrtek, A-A
                   Duenne, D Miles.
                   5:30 pm CST, Friday, Dec. 10: Fibroblast Growth Factor
                   Receptor 1 Amplification and Overexpression in Breast
                   Cancer Tissue Microarrays Using Chromogenic In Situ
                   Hybridization and Immunohistochemistry
                   -- Nuciforo P, Burzykowski T, Lambertini C, Gardner H, Liu
                   WH, Lee B, Barzaghi-Rinaudo P, Rheinhardt J, Barrett C,
                   Linnartz R, Dugan M, Hackl W, Eiermann W, Pienkowski T,
                   Crown J, Robert N, Pawlicki M, Martin M, Finn R, Lindsay M-
                   A, Slamon D, Press M.
                   5:30 pm CST, Saturday, Dec. 11: Ongoing Evaluation of
                   Capecitabine-Based Therapy in Early Breast Cancer (EBC)
                  -- Poole C, Barrios C, O'Shaughnessy J, Martin M, Mobus V.

Stephen Jones, M.D., medical director for US Oncology Research, co-chair of the US Oncology Breast Cancer Research Committee, and physician at Texas Oncology-Dallas, participated in a TEAM (Tamoxifen Exemestane Adjuvant Multinational) study that included nearly 10,000 patients over a five-year period. Study results will be presented as the following poster discussion and two poster displays:


    -- Poster Discussion:
                   7:00 am CST, Saturday, Dec. 11: Competing Causes of
                   Mortality vs. Breast Cancer Mortality at 5-years among 9766
                   postmenopausal women with hormone receptor positive early
                   breast cancer treated on the TEAM study of adjuvant
                   hormonal therapy
                   -- Stephen E. Jones, Hein Putter, Annette Hasenburg,
                   Cornelis J.H. van de Velde, Daniel Rea, Jean-Michel
                   Vannetzel, Robert Paridaens, Christos Markopoulos, Yasuo
                   Hozumi, Caroline Seynaeve.
    -- Posters:
                   5:30 pm CST, Saturday, Dec. 11: Discontinuation during
                   tamoxifen in the sequential arm of the TEAM trial of
                   adjuvant endocrine therapy in postmenopausal women with
                   hormone-sensitive early breast cancer: the effect of IES
                   results and subsequent therapy
                   -- Cornelis J. H. van de Velde, Elysee T. M. Hille, Daniel
                   Rea, Caroline Seynaeve,  Annette Hasenburg, Jean-Michel
                   Vannetzel,  Robert Paridaens, Christos Markopoulos, Yasuo
                   Hozumi,  Dirk G. Kieback,  Lina Asmar, Jan Smeets,  Johan
                   W. R. Nortier, Peyman Hadji, John M. S. Bartlett, Hein
                   Putter,  Stephen E. Jones.
                   5:30 pm CST, Saturday, Dec. 11: Effects of exemestane or
                   tamoxifen on bone health within the Tamoxifen Exemestane
                   Adjuvant Multicentre (TEAM) trial: a meta-analysis
                   --P. Hadji, L. Asmar, J.G.H. van Nes, T. Menschik, A.
                   Hasenburg, J. Kuck, H. Nortier, S.E. Jones, M. Ziller

Many clinical studies led by US Oncology Research Network physicians were also predominantly featured at numerous conferences held around the world, including the annual congress for the European Society for Medical Oncology (ESMO), the annual meeting for the American Society for Clinical Oncology (ASCO) and the American Society of Hematology (ASH) Annual Meeting and Exposition.

Those studies, along with more than 30 published manuscripts, featured forward looking clinical research topics that are helping advance cancer care today and discover improved therapies for the cancer care of tomorrow. For a complete list, please contact US Oncology at 281-863-1000.

About US Oncology

US Oncology, Inc. is the nation’s leading integrated oncology company. By uniting the largest community-based cancer treatment and research network in America, US Oncology expands patient access to high-quality care and advances the science of cancer care. Headquartered in The Woodlands, Texas, US Oncology is affiliated with 1,400 community-based oncologists, and works with patients, hospitals, payers, and the medical industry across all phases of the cancer research and delivery continuum. By promoting the use of innovative technology, clinical research, evidence-based medicine and shared best practices, US Oncology improves patient outcomes and offers a better patient experience. For more information, visit www.usoncology.com.

About US Oncology Research

US Oncology conducts clinical research through US Oncology Research, its wholly-owned subsidiary and the nation’s largest community-based cancer research network. US Oncology Research has experienced investigators and dedicated research nurses who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 90 sites in 200 locations managing more than 200 active trials at any given time. The research network has enrolled nearly 47,000 patients in more than 1,100 trials since inception in 1992 and has contributed to the development of 43 cancer therapies approved by the FDA. For more information call (866) 216-5053 or visit www.usoncology.com/oncologists.

SOURCE US Oncology


Source: newswire



comments powered by Disqus